Ivabradine
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
- Ivabradine
- Pharmacist Assessment Report
- Ivabradine: From an Unspecified Original Indication to hypertrichosis (disease)
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Ivabradine: From an Unspecified Original Indication to hypertrichosis (disease)
One-Sentence Summary
Ivabradine is a heart-rate-lowering drug that is marketed in Canada. The data compiled for this report do not state its approved indication. The TxGNN model predicts it may be effective for hypertrichosis, with a score of 0.9979. There are 0 clinical trials and 0 publications supporting this direction, so the prediction is based on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the data compiled for this report |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 0.9979 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Ivabradine is known to selectively inhibit the HCN channels (the If, or “funny”, current) in the sinoatrial node, which slows heart rate. This is general pharmacology and was not retrieved as structured data.
No established link exists between this mechanism and hair follicle biology. HCN channels are found in some tissues outside the heart, but any role in hair growth is speculative. The high TxGNN score (0.9979) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
The other predicted indications are even less supported:
| Predicted Indication | Score | Evidence Level | Assessment |
|---|---|---|---|
| Ambras type hypertrichosis universalis congenita | 0.9972 | L5 | A congenital genetic disorder (TRPS1 regulation). No plausible pathway from HCN blockade, and paediatric safety concerns (bradycardia, visual phenomena). |
| Malformation syndrome with odontal and/or periodontal component | 0.9972 | L5 | A heterogeneous developmental group. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. |
| Syndrome with a Dandy-Walker malformation as major feature | 0.9970 | L5 | A structural developmental defect. No rationale for a symptomatic cardiac drug. |
| Isolated genetic hair shaft abnormality | 0.9969 | L5 | Caused by keratin or follicle gene defects. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. |
| Nephrogenic syndrome of inappropriate antidiuresis | 0.9908 | L5 | Caused by AVPR2 gain-of-function. HCN channels exist in the kidney, but there is no evidence of relevance. This is the most biologically conceivable candidate, yet still purely speculative. |
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02459981 | LANCORA | Not available | Not available |
| 02459973 | LANCORA | Not available | Not available |
Safety Considerations
Drug Interactions: The interaction screening completed and returned 100 interacting drugs. The first 20 are listed in the data compiled for this report. Of these, 11 are rated Major and 9 are rated Moderate. The data do not explain the mechanisms. Many of the Major interactions involve drugs known to prolong the QT interval or inhibit CYP3A4, so this should be confirmed against the package insert.
- Major: aprepitant, clarithromycin, dolasetron, palonosetron, cisapride, clotrimazole, granisetron, levofloxacin, ondansetron, papaverine, cobicistat
- Moderate: famotidine, ranitidine, ranitidine (bismuth citrate), cimetidine, nizatidine, dexamethasone, metreleptin, miconazole, troglitazone
Population note: For the congenital paediatric candidates (such as Ambras syndrome), bradycardia and visual phenomena are a concern.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: All six predictions rest on the TxGNN network score alone. There are no clinical trials, no literature, and no plausible mechanistic link between HCN channel inhibition and hair growth, developmental malformation or renal water handling. Safety review also cannot proceed, because the Canadian label warnings and contraindications are not available.
To proceed, the following is needed:
- The Health Canada package insert (warnings, contraindications, approved indication, dosage form), which is a blocking gap for safety screening
- Detailed mechanism of action data from DrugBank, to support any mechanistic analysis
- Preclinical or mechanistic evidence that HCN channels play a role in hair follicle biology, if hypertrichosis is to be pursued
- A review of whether the score from the TxGNN model (deep learning) only reflects similarities the model learned between related diseases, not biological evidence
- A fuller review of the 100 detected drug interactions, with a focus on the Major ones
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.